Glenmede Investment Management, LP Replimune Group, Inc. Transaction History
Glenmede Investment Management, LP
- $19.8 Trillion
- Q2 2025
A detailed history of Glenmede Investment Management, LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Glenmede Investment Management, LP holds 25,650 shares of REPL stock, worth $238,801. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,650Holding current value
$238,801% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding REPL
# of Institutions
196Shares Held
77.6MCall Options Held
2.06MPut Options Held
2.86M-
Baker Bros. Advisors LP New York, NY11MShares$103 Million1.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$101 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$43.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.66MShares$43.4 Million5.27% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.91MShares$36.4 Million9.84% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $459M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...